Farkhanda Ghafoor ( Departments of Urology and Histopathology, National Health Research Complex, Shaikh Zayed Postgraduate Medical Institute, Lahore. )
Shahzad Khan ( Departments of Urology and Histopathology, National Health Research Complex, Shaikh Zayed Postgraduate Medical Institute, Lahore. )
Bilquis Suleman ( Departments of Urology and Histopathology, National Health Research Complex, Shaikh Zayed Postgraduate Medical Institute, Lahore. )
Aman Ullah Khan ( Departments of Urology and Histopathology, National Health Research Complex, Shaikh Zayed Postgraduate Medical Institute, Lahore. )
The present study was undertaken to evaluate the prostate specific antigen (PSA) alongwith other diagnostic methods as an application for a screening test, tumor marker and its relation to post surgical situation, The PSA has shown a sensitivity of 73.3% and specificity of 77.2%. The predictive value for positive PSA was 57% and for negative test was 66,6%. Local standards for PSA values in Pakistani community need to be established. The PSA test, inspite of its low specificity holds good promise for its contributory role as a tumor marker in prostate cancer (JPMA 48: 360,1998).
The estimated incidence of 317,000 cases and 41,000 deaths due to prostate cancer during 1996 for U.S.A. suggests that pmstate cancer (Ca) is the most common cancer and second leading cause of death from cancer among men in Un ted States1. The magnitude of the problem is not known for Pakistan, but due to improved life expectancy and socio-economic conditions, more and more males of senior ages will be exposed to this malignancy.
Prostate cancer can be detected by various methods. Digital Rectal Examination (DRE) is one of the oldest and relatively least invasive technique, but it fails to detect many cases of Ca Pmstate in their earliest stages. Various studies carried out in West showed that DRE detected Ca Prostate in the range of 0.1-1.7%2, Digital guided biopsy has anaccuracy of diagnosing Ca Prostate in 30-40% cancer cases3,4. Trans-rectal ultra sonography (TRUS) particularly random sextant biopsies also has facilitated detection of Ca prostate5,6. For over 50 years, a protein manufactured by prostate called Prostatic Acid Phosphatase (PACP) has been used as a marker for prostatic disease. Prostate specific Antigen (PSA) has emerged as a very useful markerof Ca Prostate and monitoring the effect of therapy3,4,7.
PSA was first identified in 19718 and called Y semino-pmtein. In 1978 the protein was puritied from seminal plasma and characterized as a potential semen marker9. In 1979 the protein was purified from all types of prostate tissue and was found specific in humans only, it was called Prostate Specific Antigen (PSA)10. PSA is a protease, making complexes with inhibitors in serum. The predominant complex is with “y antichymottypsin (ACT), with the minor complexes and a small free form11. Most of the commonly available immunoassay kits for PSA appear to detect both free and ACT complexes12. The normal range of PSA is known to increase with age, probably due to increase in the prostate tissue mass, which can be assessed by ultrasonography. The PSA density or index does not refer to the ‘density’ of PSA within the prostate, but rather to an index that corrects the serum PSA for the contribution from BPH. Most of the increase in PSA with age is due to increase in prostate volume. PSA density = PSA result in serum
Volume of Prostate gland
The estimates of prostate volume are often imprecise and more expensive than the PSA assay itself. The benefits in specificity described to date are usually marginal at best. However, values above the normal range 0-4 ng/ml are one of the earliest signs of prostate cancer, in many cases allowing diagnosis while the cancer is still confined to the gland13,14.
Based on the simplicity of procedure and reliability, American Cancer Society has recently recommended annual screening of men over 50 years of age15. Different iminunoassay kits may give different results in the same patient16-18. This raises the need to standardize PSA assay. Patients with greater than 10 ng/ml should be evaluated by ultrasound and needle biopsy to rule out prostate. cancer19-21. In one study a reference interval of <4 ng/ml was defined as an upper limit that was observed in all men under the age of 40 years and 97% of men over 40 years20.
Diurnal variations of PSA due to physical activity, exercise and diet have not been found. There are some racial differences in PSA levels. Ejaculation causes significant changes, PSA falls afterejaculation. Ideally PSA levels should be collected after 1-2 days of sexual abstinence. Digital rectal examination increases PSA levels, therefore one week gap is suggested following prostatic manipulation and PSA testing.
Subjects and Methods
A group of 144 males in the age rangebetween 40 to 92 years were included in the study. The cases had at least one symptom of prostatism, including frequency, urgency, weak urinary stream, dysuria or microscopic hematuria. These cases were registered at the Urology Departments of Jinnah Hospital, Shaikh Zayed Hospital and National Health Research Complex Lahore, from November, 1996 to March 1997. All subjects (100%) had neither undergone any prostate surgery nor were diagnosed as cases of cancer prostate earlier.
A comparison group of 127 subjects was included after matching for age and socio-economic standards. These subjects did not have any urinary symptoms. Serum PSA levels were measured in each subject (total of 241 cases).
All 114 cases with symptoms of prostatism underwent Transuretheral Resection of Prostate (TLJRP) or Millen’s prostatectomy for verification of diagnosis as BPH or Ca prostate. None of the control subjects underwent TURP or other procedures.
Serum PSA was measured by Immunoradiometric assay (Netna, UK). Study of the specimens was carried out by single histopathologist in the department of histopathology at Shaikh Zayed Hospital Lahore. The prostatic tissue was embedded in paraffin and stained by Hematoxylin and Eosin staining method.
This study has shown the importance of using PSA as an efficient screening test. It has not been studied for its monitoring role in the management of therapy.
Local standards for our population need to be established for suggesting more accurate Cut off values by expanding the number of subjects and including more general male population from ages 40 years and above. It has not yet been cleared as to what grade of PSA cut off value should be taken into account to suspect Ca prostate development and cases of BPH. It is possible that the PSA values for BPH are intermediate between the Ca prostate values and normal values. Thus we have to define the cut-off values for the three stages of prostate conditions (Normal, BPH and Ca prostate). In the present series 43% of Ca prostate cases were under 70 years of age who had PSA upto 4 ng/ml, while the remaining 57% of such cases were between 70-79 years of age; Among the 5 Ca prostate cases who had PSA values between 4.1-10 mg/ml, 60% were under 70 years of age. The behaviour ofPSA value for BPH was much less specific and predictable, although very few cases had the PSA values more than 30 ag/mi. It therefore seems that while age is a significant factor for the prostatic volume, otherfactors independently influence the PSA values. To obtain higher sensitivity and specificity some adjustments may also have to be taken into consideration for determinants like aging, gonadal androgenic hormones, genetic predisposition, prostatic volume and prostatic velocity. PSA testing as used currently lacks sufficient sensitivity and specificity to be considered a ‘perfect’ tumor marker for the detection of early prostate cancer. Under the present situation, use of a combination of DRE, PSA and TRUS canbe suggested to obtainbetteryields forBPH and Ca Prostate. For organ confined Ca prostate PSA based screening programme seems to hold better promise23. To improve the clinical utility of serum PSA measurements. PSA density24, PSA velocity25 and age specific reference ranges26 have been developedand evaluated. Perhaps risk assessment should be used instead of absolute cut off values, taking into account patient’s age, DRE findings as well as the free and total PSA levels.
This project is funded and technically supported by Division of Human Health International Atomic Energy Commission. The present study is a preliminary report for the initial three months. We are also extremely thankful to our colleagues from the Department of Urology, Jinnah Hospital, Lahore for their cooperation in this study.
1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, Cancer 1. Clin., 1 996;46:5-27.
2. Pedersen K, Carlsson P. Varenhorst E, et al. Screemng for carcinoma of the prostate by digital rectal examination in a randomly selected population. Br. Med.J., 1990;300:1041-4.
3. Catalona WJ, Smith DS, Ratliff TL, etal. Detection of organ- confined prostate cancer is increased through prostale specific antigen based screening. JAMA., 1993;270:954-84.
4. Catalona WJ, Richie JR Ahmann FR, et al. Comparison of digital rectal examination and serum prostatespecific antigen in theearly detection ofprostate cancer; results of multicenter clinical trial of 6,630 men. J. Urol., 1994; 15 1: 1238-90.
5. Lee F, Litirup PJ, Trop-Padersen ST. et aL Prostate cancer: Comparison of transrectal US and digital rectal examination for screening. Radiology, 1988;168:389-94.
6. Hodge KK, McNcal JE. Stamey TA. Ultrasound guided transrectal core biopsies of palpably abnormal prostate. J.Urol., 1989;142:66-70.
7. Oesterling JE. Prostate-specific antigen: a critical assessment of most useful tumor marker for the adenocarcinoma ofthe prostate. J. Urol., 1991; 145:907-23.
8. Hara H, Keyangagi Y, lneue T, et al. Some physiochemical characteristics of gamma-semino protein: An antigenie component specific for human seminal plasma. Jpn. J. Legal Med., 1971 ;25:322-4.
9. Sensabaugh OF, Crim D. Isolation and characterization of a semen specific protein from human seminal plasma: a potential new marker for semen identification J. Forensic, Sci., 1978;23: 106- 15.
10. Wang MC, Valenzuela LA, Murphy OP. et al. Purification of a human prostate specific anligen Invest. Urol. 1979,17.156-63
11. Lilja H, Nilsson 0, Pettersson K, et al. Prostate specific antigen in serum occurs predominantly in complexes with 1- antichy motrypsin. Clin. Chem., 1991;37:1618-25.
12. Denis LJ, Murphy GP, Schroder FH. Report on the consensus workshop on screening and global strategy for prostate cancer. Cancer, I 995;75: 1187-207.
13. Carter HB, Pearson JD, Metter J, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA., 1992;267:2215-20.
14. Oestcrling JE. Prostate-specific antigen: Improving its ability to diagnose early prostate cancer (editorial): JAMA., 1992;267:2236-8.
15. Mettlin C, Jones G, Averette H, et al. Defining and updating the American Cancer Society guideline for the cancer-related check- up. Prostate and endometrial cancer, CA Cancer J.Clin., 1993;43:42-6.
16. Chan DW, Bruzek DJ, Oesterling JE, et al. Prostate specific antigen ass marker for prostatic cancer: A monoclonal and a polyclonal immunoassay compared. Clin. Chem., 1987:33:1916-20.
17. Horton GL. Bahnson RR, Daft M, et al. Differences in values obtained with 2 assays of prostate specific antigen. J Urol., 1988;139:762-72.
18. Graves HCB, Wehner N, Stamey TA. Comparison of a polyclonal and monoclonal immunoassay for-PSA Need for an international antigen standard. J. Urol.. 1990;144:1516-22.
19. Cooner WI-I, Mosley BR, Rutherford CL, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol., 1990;143: 1146-52.
20. Catalona WJ, Smith DS, ZratliffTL, et al. Measurement of prostate-specific antigen in sreum as a screening test for prostate cancer. N. EngI. J. Med., 199 1;324: 1156-61.
21. Brawer MX, Chetner MP Beatie J, et al. Screening for prostate carcinoma with prostate specific antigen. J. Urol., 1992; 147:841-5.
22. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate ‘specific antigen to improve specificity of prostate cancer screening. JAMA., 1995,274,1214- 20.
23. Mosli HA. Prostalic cancer. Experience at King Abdul Aziz University Hospital,Jeddah; Annals of Saudi Medicine, 1997; 17:6.
24. Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermedial levels of serum prostate specific antigen. J. Urol. 1992; 147:817-21.
25. Cater HB, Pearson JF, Metter EJ, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA., 1992;267:22 15-20.
26. Oesterling JE, Jacobsen SJ, Chute CO. et al. Serum prostate specific antigen in community based population of healthy men. JAMA., 1993;270:840-60.